The future is now: Using the lessons learned from the ACTIV COVID-19 therapeutics trials to create an inclusive and efficient clinical trials enterprise
J Clin Transl Sci
.
2024 Oct 15;8(1):e148.
doi: 10.1017/cts.2024.622.
eCollection 2024.
Authors
Stacey J Adam
1
,
Sarah E Dunsmore
2
,
Lisa H Merck
3
,
Sarah W Read
4
,
Yves Rosenberg
5
Affiliations
1
Foundation for the National Institutes of Health, North Bethesda, USA.
2
National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, USA.
3
Department of Emergency Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
4
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA.
5
National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, USA.
PMID:
39478787
PMCID:
PMC11523011
DOI:
10.1017/cts.2024.622
No abstract available
Publication types
Editorial